Patents by Inventor Vanessa Gauttier

Vanessa Gauttier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-Chemokin Like Receptor 1 Humanized Antibodies and Their Therapeutic Applications
    Publication number: 20240084019
    Abstract: The present invention provides humanized anti-CMKLR1 compounds having an agonist capability on the interaction between Resolvin E1 and CMKLR1, and their uses for treating or preventing a disease, in particular wherein the resolution of inflammation is delayed or disrupted.
    Type: Application
    Filed: October 9, 2020
    Publication date: March 14, 2024
    Applicant: OSE IMMUNOTHERAPEUTICS
    Inventors: Vanessa Gauttier, Nicolas Poirier, Caroline Mary, Charlene Trilleaud
  • Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies
    Patent number: 11884723
    Abstract: The invention is in the field of immunotherapy. The present invention provides antibodies useful in therapeutic and diagnostic applications targeting human SIRPa, said antibodies enhancing the cross-presentation of antigens to T cells. The invention also provides antibodies against specific isoforms of SIRP a and able to disrupt the interaction between those isoforms of SIRP a and human CD47 for use in treating or preventing a disease, or diagnostic applications, and methods for producing and/or selecting anti-human SIRPa antibodies that bind with different affinities to various isoforms of human SIRP members.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: January 30, 2024
    Assignee: OSE IMMUNOTHERAPEUTICS
    Inventors: Nicolas Poirier, Vanessa Gauttier, Caroline Mary, Sabrina Pengam, Bernard Vanhove
  • ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENT THEREOF
    Publication number: 20230331852
    Abstract: The invention pertains to the field of immunotherapy. The present invention provides new specific anti-CLEC-1A compounds, in particular antibodies. The compounds of the invention are able to specifically binds to CLEC-1A receptor and antagonize the binding of CLEC-1A to its endogenous ligand(s). The use of the compounds of the invention may be useful for treating deleterious conditions.
    Type: Application
    Filed: December 4, 2020
    Publication date: October 19, 2023
    Inventors: Elise CHIFFOLEAU, Nicolas POIRIER, Ariane DESSELLE, Virginie THEPENIER, Caroline MARY, Vanessa GAUTTIER, Sabrina PENGAM
  • VACCINE AGAINST SARS-COV VIRUS
    Publication number: 20230181721
    Abstract: The present invention relates to a vaccine composition and its use against a Severe acute respiratory syndrome-related coronavirus.
    Type: Application
    Filed: May 11, 2021
    Publication date: June 15, 2023
    Inventors: DOMINIQUE COSTANTINI, ISABELLE GIRAULT, NICOLAS POIRIER, CAROLINE MARY, VANESSA GAUTTIER, AURORE MORELLO
  • METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER
    Publication number: 20220298259
    Abstract: The present disclosure concerns the use of an anti-SIRPa compound able to inhibit the polarization of anti-inflammatory M2-type macrophages and/or favors pro-inflammatory M1-type macrophages. In a preferred embodiment, such compound is used to treat cancer. Interestingly, this disclosure allows to treat cancer through an indirect pathway involving the immune system.
    Type: Application
    Filed: May 18, 2022
    Publication date: September 22, 2022
    Inventors: Nicolas Poirier, Bernard Vanhove, Vanessa Gauttier
  • ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20220281991
    Abstract: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.
    Type: Application
    Filed: February 25, 2022
    Publication date: September 8, 2022
    Inventors: Nicolas POIRIER, Caroline MARY, Bernard VANHOVE, Vanessa GAUTTIER, Virginie THEPENIER, Sabrina PENGAM
  • METHODS FOR PROMOTING T CELLS RESPONSE
    Publication number: 20220281983
    Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.
    Type: Application
    Filed: May 10, 2022
    Publication date: September 8, 2022
    Inventors: Elise CHIFFOLEAU, Geraldine TEPPAZ, Nicolas POIRIER, Bernard VANHOVE, Vanessa GAUTTIER
  • USES OF ANTI-SIRPg ANTIBODIES
    Publication number: 20220242951
    Abstract: The invention pertains to the field of immunotherapy. The present invention provides new uses of anti-SIRPg antibodies for the treatment and/or the prevention of autoimmune disorders or diseases.
    Type: Application
    Filed: January 9, 2022
    Publication date: August 4, 2022
    Inventors: NICOLAS POIRIER, CAROLINE MARY, VANESSA GAUTTIER, Virginie THEPENIER, Sabrina PENGAM, BERNARD VANHOVE
  • Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1)
    Patent number: 11365257
    Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: June 21, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, OSE IMMUNOTHERAPEUTICS
    Inventors: Elise Chiffoleau, Géraldine Teppaz, Nicolas Poirier, Bernard Vanhove, Vanessa Gauttier
  • Anti-SIRPa antibodies and their therapeutic applications
    Patent number: 11279766
    Abstract: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: March 22, 2022
    Assignee: OSE IMMUNOTHERAPEUTICS
    Inventors: Nicolas Poirier, Caroline Mary, Bernard Vanhove, Vanessa Gauttier, Virginie Thepenier, Sabrina Pengam
  • ANTI-CHEMOKIN LIKE RECEPTOR 1 ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20210147558
    Abstract: The present invention provides anti-CMKLR1 compounds having an agonist capability on the interaction between Resolvin E1 and CMKLR1, and their uses for treating or preventing a disease, in particular wherein the resolution of inflammation is delayed or disrupted.
    Type: Application
    Filed: April 3, 2019
    Publication date: May 20, 2021
    Inventors: NICOLAS POIRIER, CAROLINE MARY, BERNARD VANHOVE, VANESSA GAUTTIER, CHARLENE TRILLEAUD, MARC DUBOURDEAU
  • USE OF ANTI-HUMAN SIRPA V1 ANTIBODIES AND METHOD FOR PRODUCING ANTI-SIRPA V1 ANTIBODIES
    Publication number: 20210040206
    Abstract: The invention is in the field of immunotherapy. The present invention provides antibodies useful in therapeutic and diagnostic applications targeting human SIRPa, said antibodies enhancing the cross-presentation of antigens to T cells. The invention also provides antibodies against specific isoforms of SIRP a and able to disrupt the interaction between those isoforms of SIRP a and human CD47 for use in treating or preventing a disease, or diagnostic applications, and methods for producing and/or selecting anti-human SIRPa antibodies that bind with different affinities to various isoforms of human SIRP members.
    Type: Application
    Filed: March 13, 2019
    Publication date: February 11, 2021
    Inventors: Nicolas POIRIER, Vanessa GAUTTIER, Caroline MARY, Sabrina PENGAM, Bernard VANHOVE
  • NEW USES OF ANTI-SIRPg ANTIBODIES
    Publication number: 20190382483
    Abstract: The invention pertains to the field of immunotherapy. The present invention provides new uses of anti-SIRPg antibodies for the treatment and/or the prevention of autoimmune disorders or diseases.
    Type: Application
    Filed: February 15, 2018
    Publication date: December 19, 2019
    Inventors: NICOLAS POIRIER, CAROLINE MARY, VANESSA GAUTTIER, Virginie THEPENIER, Sabrina PENGAM, BERNARD VANHOVE
  • METHODS FOR PROMOTING T CELLS RESPONSE
    Publication number: 20190309075
    Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.
    Type: Application
    Filed: October 20, 2017
    Publication date: October 10, 2019
    Inventors: Elise CHIFFOLEAU, Géraldine TEPPAZ, Nicolas POIRIER, Bernard VANHOVE, Vanessa GAUTTIER
  • NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20190127477
    Abstract: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.
    Type: Application
    Filed: April 14, 2017
    Publication date: May 2, 2019
    Inventors: Nicolas POIRIER, Caroline MARY, Bernard VANHOVE, Vanessa GAUTTIER, Virginie THEPENIER, Sabrina PENGAM
  • METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER
    Publication number: 20180312600
    Abstract: The present disclosure concerns the use of an anti-SIRPa compound able to inhibit the polarization of anti-inflammatory M2-type macrophages and/or favors pro-inflammatory M1-type macrophages. In a preferred embodiment, such compound is used to treat cancer. Interestingly, this disclosure allows to treat cancer through an indirect pathway involving the immune system.
    Type: Application
    Filed: October 21, 2016
    Publication date: November 1, 2018
    Inventors: Nicolas Poirier, Bernard Vanhove, Vanessa Gauttier